Clinical trials: Stomach Adenocarcinoma
Gastric Adenocarcinoma, Cancer Metastatic
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study
Peritoneal metastasis is a common pattern in advanced gastric cancer leading to a terminal condition in a very short time. Whatever recent progress regarding systemic chemotherapy using multi drugs association median survival is…
- Conditions
- Gastric Adenocarcinoma, Cancer Metastatic, Chemotherapy Effect
- Trial name
- PIPAC EstoK 01 (NCT04065139)
- Testing
- Pressurized intraperitoneal aerosol chemotherapy (PIPAC), Standard chemotherapy
- Where
- France
- Volunteers
- 66 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma
The ongoing study is a Phase II, open-label study to evaluate the efficacy of MBP-426 at a dose of 170 mg/m2 in combination therapy in patients with second line metastatic gastric, gastro-esophageal junction or esophageal…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT00964080
- Testing
- MBP-426/Leucovorin/5-FU
- Where
- 5 sites in United States, Georgia
- Volunteers
- 62 people
- Sponsor
- Mebiopharm Co., Ltd
Gastric Cancer
A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer
This is a prospective pilot study to evaluate the safety and feasibility of neoadjuvant transcatheter infusion and embolism (TACiE) in patients with locally advanced adenocarcinoma of stomach and gastroesophageal junction.
- Trial name
- NCT05396326
- Testing
- Oxaliplatin, Teysuno, Transarterial arterial chemoinfusion and embolism (TACiE)
- Volunteers
- 20 people
- Sponsor
- Shanghai Zhongshan Hospital
Gastric Adenocarcinoma
Trastuzumab Based Therapy in HER2 Positive AGC
Trastuzumab plus chemotherapy is an effective therapy in HER2 positive advanced gastric cancer (AGC). However, the efficacy of routine trastuzumab therapy and its association with clinicopathologic factors remain unclear.
- Trial name
- NCT03024450
- Testing
- H+CT
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Shanghai Zhongshan Hospital
Locally Advanced Gastric Cancer
Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer
This study was designed to evaluate the efficacy and safety of camrelizumab in combination with SOX and/or apatinib in the treatment of locally advanced gastric cancer or gastroesophageal junction adenocarcinoma.The primary…
- Trial name
- CCWSA/OAFLAG (NCT04792515)
- Testing
- Camrelizumab combined with SOX/ or apatinib
- Where
- China
- Volunteers
- 67 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
Drugs used in chemotherapy such as cisplatin and fluorouracil use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach
- Trial name
- NCT00064259
- Testing
- oblimersen sodium, cisplatin, fluorouracil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
This is a multicentre, Phase Ib/II Clinical Study of AK109 and AK104 With or Without Chemotherapy in Second-line Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma .
- Trial name
- NCT04982276
- Testing
- AK109, paclitaxel, AK104
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Akeso
Lung Cancer, Gastric Cancer
INSPIRE: a Multi-Cancer Early Detection Study
This research constitutes a multi-centric, case-control designed investigation aimed at developing and implementing a blinded validation of a machine learning-powered, multi-cancer early detection model.
- Conditions
- Lung Cancer, Gastric Cancer, Liver Cancer, Colorectal Cancer
- Trial name
- INSPIRE (NCT06440018)
- Where
- China
- Volunteers
- 5,350 people
- Sponsor
- Singlera Genomics Inc.
Gastric Adenocarcinoma
Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy
This study is a single-arm, phase II study of selumetinib in combination with docetaxel in patients with advanced gastric adenocarcinoma harboring MEK signature, RAS mutation or amplification as a second line chemotherapy.
- Trial name
- NCT02448290
- Testing
- docetaxel plus selumetinib
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Samsung Medical Center
Gastric Cancer
Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial
The optimal regimen for adjuvant treatment has not been established in GC yet. We plan to compare TS-1, TS-1/oxaliplatin with or without RT in D2 resected gastric cancer.
- Trial name
- ARTIST-II (NCT01761461)
- Testing
- TS-1, oxaliplatin
- Where
- South Korea
- Volunteers
- 547 people
- Sponsor
- Samsung Medical Center
Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed…
- Conditions
- Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer
- Trial name
- NCT06047379
- Testing
- NEO212 Oral Capsule, Ipilimumab, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Neonc Technologies, Inc.
Esophageal Adenocarcinoma, Gastric Cancer
Determining Minimal Residual Disease Using ctDNA Deep Sequencing
Preoperative neoadjuvant chemotherapy is the standard treatment for locally advanced gastrointestinal tumours. However, not all patients respond to preoperative treatment.
- Conditions
- Esophageal Adenocarcinoma, Gastric Cancer, Pancreatic Cancer
- Trial name
- CIT-SEQ (NCT07660627)
- Testing
- NGS sequencing of mutations selected based on sequencing of primary tumors
- Where
- Czechia
- Volunteers
- 34 people
- Sponsor
- Masaryk Memorial Cancer Institute
Adenocarcinoma of the Stomach, Gastroesophageal Junction Expressing Guanylyl Cyclase C
A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction
The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with recurrent or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the stomach or gastroesophageal junction.
- Trial name
- NCT02202759
- Testing
- MLN0264
- Where
- 17 sites in United States, Belgium and 2 more
- Volunteers
- 38 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
This study is designed to evaluate the efficacy and safety of Camrelizumab plus pyrotinib in combination with chemotherapy in patients with HER2-positive gastric cancer.
- Trial name
- NCT05111444
- Testing
- Camrelizumab, Pyrotinib, Capecitabine
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Fudan University
Gastric Cancer
SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
Neoadjuvant chemotherapy or chemoradiotherapy has become the standard neoadjuvant regimen for locally advanced G/GEJ cancer and has been recommended by a series of treatment guidelines.
- Trial name
- NCT06266871
- Testing
- SOX+Tislelizumab+LDRT
- Volunteers
- 64 people
- Sponsor
- West China Hospital
Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase III Study of SHR-A1811 in Combination With Chemotherapy and Adebrelimab in Previously Untreated Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
This study aims to evaluate the efficacy and safety of SHR-A1811 combined with chemotherapy and immune checkpoint inhibitor versus standard first-line therapy in gastric or gastroesophageal junction adenocarcinoma.
- Trial name
- NCT07118527
- Testing
- SHR-A1811 + Adebrelimab Injection + Capecitabine Tablets or Fluorouracil Injection, Trastuzumab + Pembrolizumab + CAPOX( Capecitabine Tablets + Oxaliplatin) or FP (Fluorouracil Injection+Cisplatin)
- Where
- 2 sites in China
- Volunteers
- 600 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Gastric (Stomach) Cancer
Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to evaluate the objective response rate (ORR) of Pembrolizumab combined with Lenvatinib and SOX compared with SOX alone in the treatment of patients with HER2-negative advanced gastric or…
- Trial name
- FUGES032 (NCT07356466)
- Testing
- Pucotenlimab Combined with Lenvatinib, Oxaliplatin plus S-1 regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fujian Medical University
Anal Carcinoma, Bladder Carcinoma
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
This phase I trial is evaluating a new imaging tracer (68Ga-FAPi-46) with positron emission tomography (PET)/computed tomography (CT) to determine where and to which degree the tracer (68Ga-FAPi-46) accumulates in normal and…
- Conditions
- Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma
- Trial name
- NCT07118176
- Testing
- Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Gastric Cancer, Hepatocellular Carcinoma
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
This is a Phase II, open-label, single dose level study of PRL3-ZUMAB monotherapy in patients with advanced solid tumours that have failed standard therapy.
- Conditions
- Gastric Cancer, Hepatocellular Carcinoma, Advanced Solid Tumor
- Trial name
- NCT04118114
- Testing
- PRL3-zumab
- Where
- Singapore
- Volunteers
- 14 people
- Sponsor
- National Cancer Centre, Singapore
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.